Regeneron Pharmaceuticals.
American pharmaceutical company
Jefferies Raises Regeneron Price Target to $930
Jefferies maintained its Buy rating on Regeneron Pharmaceuticals and raised its price target from $870 to $930, citing confidence in the company’s prospects. Other analysts’ views were broadly positive, with the stock carrying a consensus Moderate Buy rating.
Business · 7 sources · 4hRead it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Everything about Regeneron Pharmaceuticals →- Country
- United States
- Headquarters
- Eastview
- Inception
- 1988
- Website
- https://www.regeneron.com/